These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8103150)

  • 1. Prescriber profile and post-marketing surveillance.
    Inman W; Pearce G
    Lancet; 1993 Sep; 342(8872):658-61. PubMed ID: 8103150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing studies: the work of the Drug Safety Research Unit.
    Mackay FJ
    Drug Saf; 1998 Nov; 19(5):343-53. PubMed ID: 9825948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilisation of extended release quetiapine (Seroquel XL™): Results from an observational cohort study in England.
    Osborne V; Davies M; Layton D; Shakir SAW
    Eur Psychiatry; 2016 Mar; 33():61-67. PubMed ID: 26872067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
    Davies M; Wilton L; Shakir S
    Drug Saf; 2013 Apr; 36(4):237-46. PubMed ID: 23483377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
    Kasliwal R; Wilton LV; Shakir SA
    Drug Saf; 2008; 31(10):839-50. PubMed ID: 18759508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
    Davies M; Wilton LV; Shakir SA
    Drug Saf; 2008; 31(4):313-23. PubMed ID: 18366242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
    Kasliwal R; Wilton LV; Cornelius V; Aurich-Barrera B; Shakir SA
    Drug Saf; 2007; 30(2):157-70. PubMed ID: 17253880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management.
    Osborne V; Hazell L; Layton D; Shakir SA
    Drug Saf; 2010 Mar; 33(3):213-21. PubMed ID: 20158285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of doctors' ethnicity and country of qualification on prescribing patterns in single handed general practices: linkage of information collected by questionnaire and from routine data.
    Gill PS; Dowell A; Harris CM
    BMJ; 1997 Dec; 315(7122):1590-4. PubMed ID: 9437279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety.
    Key C; Layton D; Shakir SA
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):143-8. PubMed ID: 11998539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of physicians' participation in non-interventional post-marketing studies on their prescription habits: A retrospective 2-armed cohort study in Germany.
    Koch C; Schleeff J; Techen F; Wollschläger D; Schott G; Kölbel R; Lieb K
    PLoS Med; 2020 Jun; 17(6):e1003151. PubMed ID: 32589633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining product risk in context. Market withdrawal of zomepirac as a case study.
    Ross-Degnan D; Soumerai SB; Fortess EE; Gurwitz JH
    JAMA; 1993 Oct; 270(16):1937-42. PubMed ID: 8411550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elderly patients in general practice: diagnoses, drugs and inappropriate prescriptions. A report from the Møre & Romsdal Prescription Study.
    Straand J; Rokstad KS
    Fam Pract; 1999 Aug; 16(4):380-8. PubMed ID: 10493709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of general practitioner prescribing of antibiotics by use of a therapeutics adviser (academic detailer).
    Ilett KF; Johnson S; Greenhill G; Mullen L; Brockis J; Golledge CL; Reid DB
    Br J Clin Pharmacol; 2000 Feb; 49(2):168-73. PubMed ID: 10671912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlates of spontaneous reporting of adverse drug reactions within primary care: the paradox of low prescribers who are high reporters.
    Cox AR; Anton C; McDowell SE; Marriott JF; Ferner RE
    Br J Clin Pharmacol; 2010 May; 69(5):529-34. PubMed ID: 20573089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.